Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02614742Phase 2Completed

SFX-01 After Subarachnoid Haemorrhage

Role: lead

NCT02970682Phase 2Completed

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

Role: lead

NCT02055716Phase 1Completed

Sulforadex in Healthy Human Males MAD

Role: lead

NCT01948362Phase 1Completed

Sulforadex in Healthy Volunteers SAD

Role: lead

All 4 trials loaded